Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mayumi Ono

Showing results (31-40 of 129) with videos related to

Pageof 13
Sort By:
Current Medicinal Chemistry|March 14, 2008
Preclinical and clinical studies of novel breast cancer drugs targeting molecules involved in protein kinase C signaling, the putative metastasis-suppressor gene Cap43 and the Y-box binding protein-1Teruhiko Fujii, Goro Yokoyama, Hiroki Takahashi, et al.
Cancer Research|May 19, 2005
HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cellsAkira Hirata, Fumihito Hosoi, Miho Miyagawa, et al.
Molecular Cancer Therapeutics|April 14, 2004
Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferationMayumi Ono, Akira Hirata, Takuro Kometani, et al.
Cancer Science|September 25, 2007
Potent inhibition of in vivo angiogenesis and tumor growth by a novel cyclooxygenase-2 inhibitor, enoic acanthoic acidHye Jin Jung, Joong Sup Shim, Young-Ger Suh, et al.
Annals of Nuclear Medicine|December 21, 2005
Radiosynthesis and in vivo evaluation of 11C-labeled 1,5-diarylpyrazole derivatives for mapping cyclooxygenasesYoshihiko Fujisaki, Kazunori Kawamura, Wei-Fang Wang, et al.
Scientific Reports|June 1, 2022
AXL/CDCP1/SRC axis confers acquired resistance to osimertinib in lung cancerYuichi Murakami, Daiki Kusakabe, Kosuke Watari, et al.
Oncology Reports|July 29, 2010
N-myc downstream-regulated gene 1/Cap43 expression promotes cell differentiation of human osteosarcoma cellsToru Matsugaki, Michihisa Zenmyo, Koji Hiraoka, et al.
Biochemical and Biophysical Research Communications|April 27, 2010
Identification of sites subjected to serine/threonine phosphorylation by SGK1 affecting N-myc downstream-regulated gene 1 (NDRG1)/Cap43-dependent suppression of angiogenic CXC chemokine expression in human pancreatic cancer cellsYuichi Murakami, Fumihito Hosoi, Hiroto Izumi, et al.
Chemical & Pharmaceutical Bulletin|June 17, 2003
1,3-dimethylisoguaninium, an antiangiogenic purine analog from the sponge Amphimedon paraviridisSei-Joon Jeong, Masanori Inagaki, Ryuichi Higuchi, et al.
Molecular Cancer Therapeutics|November 15, 2011
Overcoming erlotinib resistance in EGFR mutation-positive non-small cell lung cancer cells by targeting survivinKunio Okamoto, Isamu Okamoto, Erina Hatashita, et al.
Pageof 13

Showing results (31-40 of 129) with videos related to

Sort By:
Pageof 13
Current Medicinal Chemistry|March 14, 2008
Preclinical and clinical studies of novel breast cancer drugs targeting molecules involved in protein kinase C signaling, the putative metastasis-suppressor gene Cap43 and the Y-box binding protein-1Teruhiko Fujii, Goro Yokoyama, Hiroki Takahashi, et al.
Cancer Research|May 19, 2005
HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cellsAkira Hirata, Fumihito Hosoi, Miho Miyagawa, et al.
Molecular Cancer Therapeutics|April 14, 2004
Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferationMayumi Ono, Akira Hirata, Takuro Kometani, et al.
Cancer Science|September 25, 2007
Potent inhibition of in vivo angiogenesis and tumor growth by a novel cyclooxygenase-2 inhibitor, enoic acanthoic acidHye Jin Jung, Joong Sup Shim, Young-Ger Suh, et al.
Annals of Nuclear Medicine|December 21, 2005
Radiosynthesis and in vivo evaluation of 11C-labeled 1,5-diarylpyrazole derivatives for mapping cyclooxygenasesYoshihiko Fujisaki, Kazunori Kawamura, Wei-Fang Wang, et al.
Scientific Reports|June 1, 2022
AXL/CDCP1/SRC axis confers acquired resistance to osimertinib in lung cancerYuichi Murakami, Daiki Kusakabe, Kosuke Watari, et al.
Oncology Reports|July 29, 2010
N-myc downstream-regulated gene 1/Cap43 expression promotes cell differentiation of human osteosarcoma cellsToru Matsugaki, Michihisa Zenmyo, Koji Hiraoka, et al.
Biochemical and Biophysical Research Communications|April 27, 2010
Identification of sites subjected to serine/threonine phosphorylation by SGK1 affecting N-myc downstream-regulated gene 1 (NDRG1)/Cap43-dependent suppression of angiogenic CXC chemokine expression in human pancreatic cancer cellsYuichi Murakami, Fumihito Hosoi, Hiroto Izumi, et al.
Chemical & Pharmaceutical Bulletin|June 17, 2003
1,3-dimethylisoguaninium, an antiangiogenic purine analog from the sponge Amphimedon paraviridisSei-Joon Jeong, Masanori Inagaki, Ryuichi Higuchi, et al.
Molecular Cancer Therapeutics|November 15, 2011
Overcoming erlotinib resistance in EGFR mutation-positive non-small cell lung cancer cells by targeting survivinKunio Okamoto, Isamu Okamoto, Erina Hatashita, et al.
Pageof 13